The impact of estrogen status on the biological function of brown adipose tissue in women measured using quantitative PET/CT
The physiological relevance of brown adipose tissue in humans is largely unknown. We have shown that suppressing ovarian function in premenopausal women reduces resting energy expenditure (REE), and this is prevented by adding back estradiol (E2). Our preliminary data suggest that this may...
Protocol #: 16-1479
|
Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics
Inclusion criteria:
- Women aged 18-55 years
- Non-smoking
- Not taking medications to treat high blood pressure or cholesterol
...
Protocol #: 21-3590
|
A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors
Protocol #: 22-0359
Location: University of Colorado Hospital
|
PICCOLO: A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Protocol #: 21-4369
Location: University of Colorado Hospital
|
A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum-Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)
Protocol #: 21-4100
Location: University of Colorado Hospital
|
First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors
Protocol #: 21-3039
Location: University of Colorado Hospital
|
A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Protocol #: 20-2818
Location: University of Colorado Hospital
|
NRG-CC008: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROC]
Protocol #: 20-2079
Location: Highlands Ranch Hospital, Memorial Hospital Central, Memorial Hospital North, University of Colorado Hospital
|
A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma (FLORA-5)
Protocol #: 20-1026
Location: University of Colorado Hospital
|
S1714: A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane Induced Peripheral Neuropathy in Cancer Patients
Protocol #: 19-2216
Location: Rocky Mountain Regional VA Medical Center
|
NRG-GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Protocol #: 19-2797
Location: University of Colorado Hospital
|
A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
Protocol #: 19-2640
Location: Rocky Mountain Regional VA Medical Center
|
Post-Prandial Liver Glucose Metabolism in Polycystic Ovarian Syndrome (PCOS) and understanding Standard of Care Medications
Protocol #: 16-2399
Location: Outpatient CTRC, Outpatient CTRC, University of Colorado Hospital
|
